Thailand antirheumatic drugs market was valued at US$915.846 million in 2019. The rising rate of disease prevalence including osteoarthritis and rheumatoid arthritis in Thailand is the major driver of antirheumatic drugs market in the country. Unhealthy lifestyle has resulted in an increases burden of various chronic diseases such as obesity and diabetes in Thailand which can cause arthritis, gout, and lupus as well. According to the country’s Ministry of Public Health, more than 3 million people are now living with diabetes in Thailand, equal to one in ten people in the country. Increasing efforts to boost the domestic pharmaceutical industry is also a driving factor for the market growth of antirheumatic drugs in this country. The Government of Thailand is taking initiatives to extend health insurance coverage while promoting the production and use of cheaper OTC drugs. The presence of major market players also supports the market growth of antirheumatic drugs in Thailand.
Thailand antirheumatic drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, the Thailand antirheumatic drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).